Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
04.11. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment | 228 | ACCESSWIRE | Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael WellerAccess the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc.... ► Artikel lesen | |
01.11. | CNS Pharmaceuticals erhält Fristverlängerung für Nasdaq-Compliance | 1 | Investing.com Deutsch | ||
01.11. | CNS Pharmaceuticals granted Nasdaq compliance extension | 1 | Investing.com | ||
01.11. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement | 166 | ACCESSWIRE | HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
01.11. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
23.10. | CNS Pharmaceuticals secures $3 million in registered direct offering | 8 | Investing.com | ||
23.10. | CNS Pharmaceuticals sichert sich 3 Millionen US-Dollar durch registrierte Direktplatzierung | 2 | Investing.com Deutsch | ||
CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
23.10. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | 284 | ACCESSWIRE | HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
23.10. | CNS Pharmaceuticals droht Delisting von der NASDAQ aufgrund von Preisregel | 5 | Investing.com Deutsch | ||
23.10. | Why CNS Pharmaceuticals (CNSP) Stock Is Up 86% | 4 | Benzinga.com | ||
23.10. | CNS Pharmaceuticals faces NASDAQ delisting over price rule | 3 | Investing.com | ||
23.10. | Pre-market Movers: CNS Pharmaceuticals, Zapata Computing, Farmmi, Mustang Bio, Spirit Airlines | 316 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.35 A.M. ET).In the Green CNS Pharmaceuticals, Inc. (CNSP) is up over 143%... ► Artikel lesen | |
23.10. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 15 | SEC Filings | ||
10.10. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment | 185 | ACCESSWIRE | Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel GoldlustAccess the segment here HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS... ► Artikel lesen | |
08.10. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC | 234 | ACCESSWIRE | Live webcast fireside chat on Wednesday, October 16th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical... ► Artikel lesen | |
23.09. | BioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum | 4 | iNVEZZ.com | ||
23.09. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum | 177 | ACCESSWIRE | Webcast presentation on Wednesday, September 25th at 1:55 PM CEST HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical... ► Artikel lesen | |
12.09. | CNS Pharmaceuticals erfüllt wieder NASDAQ-Anforderungen | 3 | Investing.com Deutsch | ||
12.09. | CNS Pharmaceuticals regains Nasdaq compliance | 3 | Seeking Alpha | ||
12.09. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement | 123 | ACCESSWIRE | HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 2,730 | +0,81 % | EQS-News: CureVac veröffentlicht am 12. November 2024 Finanzergebnisse des dritten Quartals sowie der ersten neun Monate 2024 und informiert über seine Geschäftsentwicklung | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Quartalsergebnis
CureVac veröffentlicht am 12. November 2024 Finanzergebnisse des dritten Quartals sowie der ersten neun Monate... ► Artikel lesen | |
CORE ONE LABS | 0,079 | -100,00 % | XFRA LD6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCORE ONE LABS INC.... ► Artikel lesen | |
REDHILL BIOPHARMA | 7,200 | -8,75 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
G1 THERAPEUTICS | 6,345 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 18.09.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 18.09.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 18.09.2024ISIN NameCA05461V2012 AXMIN... ► Artikel lesen | |
WINDTREE THERAPEUTICS | 0,578 | 0,00 % | WINT stock touches 52-week low at $0.62 amid sharp annual decline | ||
NUCANA | 1,440 | -2,04 % | NuCana plc: NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel | Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival Following... ► Artikel lesen | |
CINGULATE | 4,140 | 0,00 % | Cingulate Inc.: Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market | KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology... ► Artikel lesen | |
GALMED | 6,500 | -100,00 % | Galmed Phar stock hits 52-week low at $2.73 amid challenges | ||
SCISPARC | 0,238 | 0,00 % | SciSparc Ltd: SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment | FDA confirms that SciSparc's study may proceed only a month after application submission TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc")... ► Artikel lesen | |
ONCONETIX | 1,800 | -9,09 % | Onconetix, Inc. - S-1/A, General form for registration of securities | ||
PORTAGE BIOTECH | 4,090 | 0,00 % | Pre-market Movers: Portage Biotech, Veea, Intuitive Machines, Applied Therapeutics, Galmed Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Portage Biotech Inc. (PRTG) is up over 179% at... ► Artikel lesen | |
BIOCARDIA | 2,370 | 0,00 % | BioCardia, Inc.: BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure | SUNNYVALE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases... ► Artikel lesen | |
ENSYSCE BIOSCIENCES | 0,671 | 0,00 % | Ensysce Biosciences, Inc.: Ensysce Biosciences Reports Third Quarter 2024 Financial Results | Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPARSubmitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / ACCESSWIRE... ► Artikel lesen | |
DERMATA THERAPEUTICS | 1,290 | -4,44 % | Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 | SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical... ► Artikel lesen | |
TELESIS BIO | 3,150 | -21,05 % | Telesis Bio secures $3 million in promissory notes |